# Tarsus Pharmaceuticals, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Tarsus Pharmaceuticals, Inc.). ## Overview Tarsus Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing ophthalmic and other specialty therapeutics built around lotilaner and related formulations. Its business combines a marketed eye-care product, XDEMVY, with a pipeline that includes product candidates for ocular rosacea and Lyme disease prophylaxis. ## Products & services • XDEMVY (lotilaner ophthalmic solution) 0.25% • TP-04 topical gel for ocular rosacea • TP-05 oral formulation for Lyme disease prophylaxis • Clinical development and regulatory approval activities • Commercialization, marketing, and distribution of eye-care therapeutics - **Commercial ophthalmology product** (85%) — Approved prescription eye-care therapy sold for Demodex blepharitis. - **Clinical-stage ophthalmology pipeline** (10%) — Development programs for ocular rosacea and related eye conditions. - **Licensing and collaboration revenue** (5%) — Revenue from out-licensing and clinical supply arrangements. - XDEMVY (lotilaner ophthalmic solution) 0.25% - TP-04 topical gel for ocular rosacea - TP-05 oral formulation for Lyme disease prophylaxis - Clinical development and regulatory approval activities - Commercialization, marketing, and distribution of eye-care therapeutics ## Customers Tarsus sells primarily to eye care professionals who prescribe XDEMVY for patients with Demodex blepharitis. Its commercial model also depends on payers and pharmacy channels that determine access, coverage, and patient affordability. In development programs, the company’s future customers would include ophthalmologists, dermatology-adjacent specialists, and patients with ocular inflammatory conditions if approvals are obtained. - **Eye care professionals** (primary) — Ophthalmologists and optometrists prescribe XDEMVY and drive adoption through diagnosis and treatment decisions. - **Patients with Demodex blepharitis** (primary) — Patients buy the therapy through prescriptions to treat a specific eyelid condition and related symptoms. - **Payers and covered lives** (primary) — Commercial insurers, Medicare, and Medicaid affect formulary access and out-of-pocket affordability. - **Pharmacy and distribution partners** (secondary) — Specialty and dispensing channels fulfill prescriptions and support commercial reach. - **Clinical trial and future specialty prescribers** (emerging) — Specialists who may adopt TP-04 or TP-05 if those programs reach approval. - Eye care professionals prescribing XDEMVY for Demodex blepharitis - Patients seeking treatment for chronic eyelid inflammation and irritation - Commercial, Medicare, and Medicaid covered lives influencing access - Pharmacy and distribution channels that dispense the product - Potential future prescribers for ocular rosacea and Lyme prophylaxis ## Geography Tarsus is headquartered in the United States and generates most of its commercial activity there through XDEMVY. The company also has a China out-license and clinical supply agreement that contributes collaboration revenue, while manufacturing and supply chain activities rely on third-party partners, including some outside the U.S. Geography matters because the business is concentrated in the U.S. commercial eye-care market but exposed to cross-border manufacturing, regulatory, and licensing arrangements. - **United States** (95%) — Primary commercial market for XDEMVY and most operating activity. - **China** (5%) — Out-license and clinical supply collaboration revenue. - United States is the core commercial market for XDEMVY - China contributes collaboration revenue through an out-license - Third-party manufacturing and supply chain partners are partly offshore - U.S. payer coverage is important for prescription access and uptake - International supply and regulatory dependencies affect commercialization ## Strategy Tarsus is focused on expanding XDEMVY adoption in Demodex blepharitis while maintaining regulatory, manufacturing, and supply continuity. It is also building a broader ophthalmology pipeline around TP-04 and TP-05 and may use collaborations or licensing to extend reach and fund development. Protecting intellectual property and expanding commercial infrastructure are central to its strategy because the company competes in a crowded specialty-pharma market. - **Grow XDEMVY commercial adoption** (short-term) — The approved product is the main revenue engine and validates the category. - **Advance the pipeline** (medium-term) — Additional approved products would diversify revenue and reduce single-product dependence. - **Secure supply chain and manufacturing capacity** (short-term) — Commercial continuity depends on reliable lotilaner supply and drug product manufacturing. - **Protect intellectual property and partnering optionality** (long-term) — Patent and licensing strength support pricing power and future collaboration value. - Expand XDEMVY adoption in the Demodex blepharitis market - Maintain regulatory approval and supply reliability for the commercial product - Advance TP-04 for ocular rosacea and TP-05 for Lyme prophylaxis - Protect and expand intellectual property around lotilaner-based programs - Use collaborations or licensing to support development and commercialization ## Risks Tarsus is exposed to single-product concentration, clinical development risk, and dependence on third-party manufacturers and suppliers. As a biopharmaceutical company, it also faces regulatory, reimbursement, intellectual property, and competitive risks that can affect adoption, pricing, and the timing of future approvals. - **Single-product dependence** [high] — Most commercial revenue is tied to XDEMVY, so any slowdown would materially affect results. - **Clinical development failure** [high] — TP-04 and TP-05 are still in development and may not show sufficient efficacy or safety. - **Manufacturing and supplier concentration** [high] — The company has relied on a limited number of suppliers and CMOs for lotilaner and drug product. - **Reimbursement and access risk** [medium] — Coverage decisions by commercial and government payers affect prescription volume and net sales. - **Competitive pressure** [medium] — Other prescription and off-label treatments can limit market share and pricing power. - Heavy dependence on XDEMVY creates single-product concentration risk - Clinical programs may fail, delay, or not achieve approval - Third-party manufacturing and supply disruptions could limit sales - Payer coverage and reimbursement can constrain patient access - Competition from larger pharma and off-label treatments may slow adoption ## Accounting The most important accounting judgments for Tarsus center on revenue recognition for product sales, rebates, and collaboration revenue. Investors should also watch estimates for gross-to-net deductions, inventory and supply-related costs, and the valuation of any capitalized or acquired intangible assets tied to development programs and licensing arrangements. - **Gross-to-net revenue reserves** — Affects reported net product sales and quarterly comparability - **Collaboration and license revenue recognition** — Can create uneven revenue timing across periods - **Inventory and launch-related costs** — Can affect margins and working capital - **Impairment of development assets** — Potential write-downs if programs underperform - Gross-to-net reserves affect reported net product sales - Rebates and payer discounts require judgment and can shift revenue timing - Collaboration and license revenue depends on contract terms and milestones - Inventory and supply-chain costs can be sensitive to launch volumes - Development-stage assets may face impairment if programs stall --- *Last updated: 2026-04-29T05:03:02.990621+00:00*